In recent trials, patients with HER2+ breast cancer (BC) have been reported as deriving clinically meaningful benefits from subsequent administration of HER2 inhibitors, such as lapatinib, pertuzumab, and T-DM1. The gene discussed is ERBB2; the disease is breast cancer.